Looking Beyond Th17 Cells: A Role for Th17.1 Cells in Thyroid-associated Ophthalmopathy?

IFN-γ IL-17A Th17 cells Th17.1 cells thyroid-associated ophthalmopathy

Journal

Endocrinology
ISSN: 1945-7170
Titre abrégé: Endocrinology
Pays: United States
ID NLM: 0375040

Informations de publication

Date de publication:
09 01 2023
Historique:
received: 26 10 2022
pubmed: 11 1 2023
medline: 2 2 2023
entrez: 10 1 2023
Statut: ppublish

Résumé

Thyroid-associated ophthalmopathy (TAO), an ordinary extrathyroid syndrome of Graves' disease (GD), is closely associated with immunity. T helper (Th) 17, Th1, and Th2 cells in Th lineages are thought to be related to the disease pathogenesis. Recently, there has been growing evidence that Th17.1 cells are involved in the development and progression of TAO. The characteristics of this pathology are similar to those of Th1 and Th17 lymphocytes, which secrete interferon (IFN)-γ and interleukin (IL)-17A. This paper reviews the potential role of the Th17.1 subgroup pathogenesis of TAO. The therapeutic effects of drugs that can modulate Th17.1 cell populations are also highlighted. Rich Th17.1 cells exist in peripheral blood and ocular tissues of patients suffering from thyroid eye disease (TED), especially those with severe or steroid-resistant TAO. The bias of Th17.1 cells to secrete cytokines partly determines the pathological outcome of TAO patients. Th17.1 cells are important in regulating fibrosis, adipocyte differentiation, and hyaluronic acid production. In summary, the Th17.1 subpopulation is essential in the onset and progression of TED, and targeting Th17.1 cell therapy may be a promising therapeutic approach.

Identifiants

pubmed: 36624983
pii: 6980482
doi: 10.1210/endocr/bqad004
pii:
doi:

Substances chimiques

Cytokines 0

Types de publication

Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Minmin Jiang (M)

First School of Clinical Medicine, Henan University of Chinese Medicine, Zhengzhou 450000, China.

Yu Fu (Y)

Department of Endocrinology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China.

Ping Wang (P)

First School of Clinical Medicine, Henan University of Chinese Medicine, Zhengzhou 450000, China.

Yan Yan (Y)

First School of Clinical Medicine, Henan University of Chinese Medicine, Zhengzhou 450000, China.

Jingxiao Zhao (J)

First School of Clinical Medicine, Henan University of Chinese Medicine, Zhengzhou 450000, China.

Ying Wang (Y)

International Medical Faculty, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.

Shuxun Yan (S)

Department of Endocrinology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH